Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 12/20 | 0.42 |
| ▸ | SCN1A | P35498 | 11/20 | 0.42 |
| ▸ | STS | P08842 | 2/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634014 | 0.94 | SCN1A (0.42) | SCN8ASCN1ASTSBMP1SLC2A1 | |
| SCHEMBL19613480 | 0.94 | SCN1A (0.42) | SCN8ASCN1ASTSBMP1SLC2A1 | |
| SCHEMBL19631502 | 0.94 | SCN1A (0.42) | SCN8ASCN1ASTSBMP1SLC2A1 | |
| SCHEMBL19627603 | 0.91 | SCN8A (0.46) | SCN8ASCN1ASTSBMP1 | |
| SCHEMBL19627640 | 0.90 | SCN8A (0.41) | SCN8ASCN1ASTSBMP1NPC1 | |
| SCHEMBL19627609 | 0.87 | CNR1 (0.41) | SCN8ASCN1ASTSBMP1SLC2A1 | |
| SCHEMBL19627633 | 0.87 | CNR1 (0.41) | SCN8ASCN1ASTSBMP1SLC2A1 | |
| SCHEMBL19627637 | 0.86 | SCN8A (0.43) | SCN8ASCN1A | |
| SCHEMBL19627635 | 0.86 | SCN8A (0.43) | SCN8ASCN1A | |
| SCHEMBL19627610 | 0.85 | SCN8A (0.40) | SCN8ASCN1ASTSBMP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885STS 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.